Zepatier

3 Bright Spots in Merck's Q3 Results
3 Bright Spots in Merck's Q3 Results
Motley Fool
Merck
earnings
Keytruda
Zepatier
animal health
Flag link:
Merck targets high-risk military veterans for hepatitis C lessons
Merck targets high-risk military veterans for hepatitis C lessons
Fierce Pharma
Merck
hepatitis C
Zepatier
Flag link:
10 Reasons Merck Could Be the World's Most Perfect Stock
10 Reasons Merck Could Be the World's Most Perfect Stock
Motley Fool
Merck
Keytruda
Zepatier
biosimilars
M&A
drug pricing
animal health
Flag link:
This Was, Unquestionably, the Most Disappointing Drug Launch of 2016
This Was, Unquestionably, the Most Disappointing Drug Launch of 2016
Motley Fool
drug launches
Merck
Zepatier
hepatitis C
Flag link:
Zepatier Should Boost Merck’s Profit Margins in the Future
Zepatier Should Boost Merck’s Profit Margins in the Future
Market Realist
Merck
Zepatier
hepatitis C
Flag link:
Merck's Mixed Q1 Results Are Marred By 1 Disappointing Drug Debut
Merck's Mixed Q1 Results Are Marred By 1 Disappointing Drug Debut
Motley Fool
Merck
earnings
Zepatier
hepatitis C
Flag link:
'Aggressive' pricing helps Merck steal hep C share with newcomer Zepatier
'Aggressive' pricing helps Merck steal hep C share with newcomer Zepatier
BioPharma Dive
drug pricing
Merck
hepatitis C
Zepatier
Flag link:
Seven New York insurers end restrictions on coverage for hepatitis C drugs
Seven New York insurers end restrictions on coverage for hepatitis C drugs
BioPharma Dive
New York
insurers
hepatitis C
Merck
Zepatier
Gilead Sciences
Harvoni
Flag link:
New analysis boosts cost-effectiveness argument for Merck's Zepatier
New analysis boosts cost-effectiveness argument for Merck's Zepatier
BioPharma Dive
Merck
Zepatier
hepatitis C
Harvoni
Gilead Sciences
Flag link:
Merck's 'no patient left behind' approach to hepatitis C
Merck's 'no patient left behind' approach to hepatitis C
BioPharma Dive
Merck
hepatitis C
Zepatier
Gilead Sciences
Sovaldi
Harvoni
Flag link:
Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
Yahoo
Merck
Zepatier
elbasvir/grazoprevir
hepatitis C
Flag link:
Gilead Sciences: ‘Another Pretender to Hepatitis C Throne Seems to Be Suffering the AbbVie Fate’
Gilead Sciences: ‘Another Pretender to Hepatitis C Throne Seems to Be Suffering the AbbVie Fate’
Barron's
Gilead Sciences
hepatitis C
Merck
Zepatier
Harvoni
Flag link:
Will Merck Encroach On Gilead's Harvoni Territory?
Will Merck Encroach On Gilead's Harvoni Territory?
Yahoo/Benzinga
Merck
Gilead
Harvoni
AbbVie
hepatitis C
Viekira Pak
Zepatier
Flag link:
Merck's new hep C contender Zepatier faces a long runway, but 2017 could bring takeoff
Merck's new hep C contender Zepatier faces a long runway, but 2017 could bring takeoff
Fierce Pharma Marketing
Merck
hepatitis C
Zepatier
Express Scripts
Flag link:
Curing Hepatitis C: How Gilead Sciences Plans to Beat Merck
Curing Hepatitis C: How Gilead Sciences Plans to Beat Merck
Motley Fool
hepatitis C
Merck
Gilead Sciences
Zepatier
Harvoni
Flag link:
Merck Takes on Gilead With Sharply Lower Hepatitis C Drug Price
Merck Takes on Gilead With Sharply Lower Hepatitis C Drug Price
TheStreet.com
Merck
Gilead Sciences
hepatitis C
Zepatier
drug pricing
Flag link: